受产量下降和液化天然气出口量增加推动，美国天然气期货价格涨超5%。

克里姆林宫：泽连斯基最近关于停火的言论是由于乌克兰军事和经济形势恶化所致。

Novo Nordisk's CEO said the company must do more to rebuild investor trust as flagship drugs including Ozempic and Wegovy face patent expiries in the US and Europe over the next decade. He warned that overpromising and under-delivering quickly erodes confidence and that investors want clarity on the company's next steps. Shares fell on Monday after an investor day disappointed with limited detail on the turnaround plan. Ozempic and Wegovy account for roughly three-quarters of sales. Novo Nordisk has pledged to launch more than five major drugs by 2030 and to add over $23 bln in incremental sales by 2035; analysts say those targets largely meet expectations. BMO Capital Markets said the company remains in a proof-of-performance phase and investors need clearer visibility on next-generation drugs and likely market uptake to restore confidence.